5 assets in Salivary Gland Carcinoma

Therapeutic assets addressing Salivary Gland Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Salivary Gland Carcinoma	VM Oncology, LLC	P2	B (60)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- Salivary Gland Carcinoma	VM Oncology, LLC	P1/2	CCC (48)
Ceralasertib Salivary Gland Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Fludeoxyglucose Salivary Gland Carcinoma	Jonsson Comprehensive Cancer Center	P1	CC (43)
Trastuzumab Deruxtecan Salivary Gland Carcinoma	National Cancer Institute (NCI)	P1	CC (43)